Back to top

gene-therapy: Archive

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNPositive Net Change BEAMPositive Net Change NTLAPositive Net Change

Zacks Equity Research

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.

SRPTPositive Net Change RNAPositive Net Change ARWRPositive Net Change PEPGPositive Net Change

Zacks Equity Research

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

RHHBYPositive Net Change ALKSPositive Net Change SRPTPositive Net Change CRMDPositive Net Change